Form 4: Kronos Bio Interim CEO Sells Shares to Cover Tax Obligations

Deborah Knobelman, President and Interim CEO of Kronos Bio, Inc., reported the sale of 24,838 shares of common stock on June 5, 2025, to satisfy estimated tax withholding obligations.

Summary

• Deborah Knobelman, the President and Interim CEO of Kronos Bio, Inc. (KRON), reported a transaction involving the company's common stock.
• On June 5, 2025, Ms. Knobelman disposed of 24,838 shares of common stock.
• The shares were sold at a price of $0.8678 per share.
• The purpose of this sale was to satisfy estimated tax withholding obligations arising from the settlement of restricted stock units.
• Following this transaction, Ms. Knobelman beneficially owns 139,422 shares of Kronos Bio, Inc. common stock.
• The Form 4 filing was signed and dated June 6, 2025.

Sentiment

Score: 5

Explanation: The transaction is a routine sale of shares to cover tax obligations upon RSU vesting, which is a neutral event for the company's operational performance and does not reflect a change in management's confidence in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The reported transaction 'Represents shares sold to satisfy estimated tax withholding obligations upon the settlement of restricted stock units.'

Industry Context

This Form 4 filing details a routine insider transaction, specifically a sale of shares by an executive to cover tax obligations related to equity compensation. Such transactions are common across all industries when restricted stock units or similar equity awards vest.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, tax-related sale of shares by an executive, not a discretionary sale indicating a lack of confidence.

Key Dates

Keywords

Kronos Bio, KRON, Form 4, insider trading, stock sale, restricted stock units, tax withholding, Deborah Knobelman, CEO